Clinical trial NCT01124708: Efficacy, Safety, and Tolerability of TC-5619 in Adults With Attention Deficit/Hyperactivity Disorder (ADHD)
Official title: A Double-blind, Randomized, Placebo-controlled, Multicenter, Fixed Dose Titration Study to Assess Efficacy, Safety, and Tolerability of TC-5619 in Adults With Attention Deficit/Hyperactivity Disorder (ADHD)
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: PHASE2
Conditions: ADHD
Keywords: ADHD
Attention Deficit Hyperactive Disorder
Lead sponsor: Targacept Inc.
Sponsor class: INDUSTRY
First posted: 2010-05-17
Enrollment: 134
Sex: ALL
Minimum age (years): 18
Maximum age (years): 65
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: yes
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: TREATMENT

Brief summary: ADHD has been associated with persistent deficits in the efficient allocation of attention and supports the notion that regulation of the cholinergic system may improve these cognitive deficits in ADHD. It has been suggested that the effects of nicotine are most pronounced on tasks that demand effortful processing (Rusted and Warburton 1994). In addition, a recent theory proposes that the cholinergic system allocates additional attentional resources during tasks that are demanding (i.e. sustained attention, set shifting, etc; Sarter and Bruno 1997). Thus it may be that in ADHD, cholinergic systems are under-responsive or under-developed and thus stimulation of nicotinic receptors via nicotinic agents may result in improved cognitive performance particularly on tests requiring effortful processing.

Detailed description: A randomized, parallel, forced-titration design is being used to assess effects of TC-5619 versus placebo on efficacy. A parallel group design allows the effects of TC-5619 to be clearly established, and the randomized nature of the design allows minimization of observer and subject bias. Because a forced dose up-titration design will be used, effects of individual doses will be preliminary, because the design confounds dose with time.

The doses chosen (1mg, 5mg, and 25mg) reflect an appropriate range around the anticipated efficacious dose (3-10 mg), based upon preclinical extrapolations to the human, and upon the pro-cognitive effects of TC-5619 identified by CDR in the MRD study (Targacept Study TC-5619-238-CLP-002).

All subjects will be tobacco non-users. It is possible that tobacco (nicotine) interferes with α7 NNR-mediated effects.

Eligibility criteria: Inclusion Criteria:

1. Diagnosis of ADHD per DSM-IV TR criteria
2. Score \> 2 on at least 6 of 9 items in at least 1 subscale of the CAARS-INV
3. Score \> 4 (at least moderate) on the Clinical Global Impression-Severity (CGI-S) index
4. Age 18 - 65, male or female
5. Tobacco non-users as indicated by lack of tobacco use within the last year prior to Screening, and by negative urinary cotinine level of \< 50ng/mL after quantification
6. Able to understand and sign informed consent

Exclusion Criteria:

1. Current DSM-IV Axis I psychiatric disorder other than ADHD; use of MINI to exclude other major DSM-IV TR psychiatric diagnoses
2. Known or suspected drug abuse within the last 12 months prior to Screening
3. Urine drug screen positive for illegal or non-prescribed drugs at Screening
4. Patients at imminent risk of suicide or of danger to themselves or others
5. Use of drugs affecting cognitive function within 3 weeks prior to Day 1, including use of any medications for treatment of ADHD. Any medication wash-outs must be completed during the 3 weeks between Screening and Day 1.
6. Any other restricted or prohibited drugs.
7. Other concomitant medications that have been changed within 4 weeks prior to Screening
8. Unable to comply with study procedures in opinion of investigator, including CogState ADHD test battery
9. History of significant other major or unstable neurological, metabolic, hepatic, renal, hematological, pulmonary, CV, GI, or urological disorder; or diagnosis of major depressive disorder
10. Myocardial infarction within past year
11. Seizure disorder within past year
12. Type 1 diabetes mellitus (DM); type 2 DM that requires medication (diet-controlled allowed)
13. HbA1C \> 7.4 at Screening
14. BMI \< 15 or \> 35; male weight \< 100 lbs; female weight \< 80 lbs.
15. Current TB or known systemic infection (HBV, HCV, HIV)
16. Clinically significant finding on physical exam
17. Clinically significant lab or ECG abnormality that could be a safety issue in the study, including QTcF \> 450 (males) or QTcF \> 480msec (females), and excluding LFTs \> 1.5 times upper limits of normal
18. Women of child-bearing potential and men unwilling or unable to use accepted methods of birth control
19. Women with a positive pregnancy test, or who are lactating
20. Participation in another clinical trial in last 3 months prior to Screening

Primary outcomes:
measure: CAARS-INV ADHD-rating scale
timeFrame: Week 12
Secondary outcomes:
measure: CAARS-INV subscales
timeFrame: Week 12
measure: CogState ADHD Battery
timeFrame: Week 12
measure: CogState Stop-Signal Task scores
timeFrame: Week 12
measure: CAARS-Self Rating (CAARS-S) total score
timeFrame: Week 12
Other outcomes:
Locations:
city: Bradenton
country: United States
facility: Florida Clinical Research Center, LLC
state: Florida
city: Jacksonville
country: United States
facility: Clinical Neuroscience Solutions, Inc.
state: Florida
city: Lauderhill
country: United States
facility: Fidelity Clinical Research, Inc
state: Florida
city: Maitland
country: United States
facility: Florida Clinical Research Center, LLC
state: Florida
city: North Miami
country: United States
facility: Scientifc Clinical Research, Inc.
state: Florida
city: Orlando
country: United States
facility: Clinical Neuroscience Solutions, Inc.
state: Florida
city: Atlanta
country: United States
facility: Atlanta Center For Clinical Research
state: Georgia
city: Willingboro
country: United States
facility: CRI Worldwide, LLC (Lourdes Division)
state: New Jersey
city: Canton
country: United States
facility: Neuro-Behavioral Clinical Research, Inc.
state: Ohio
city: Dayton
country: United States
facility: Midwest Clinical Research Center
state: Ohio
city: Portland
country: United States
facility: Oregon Center For Clinical Investigations, Inc. (OBBI, Inc.)
state: Oregon
city: Philadelphia
country: United States
facility: CRI Worldwide, LLC (Kirkbride Division)
state: Pennsylvania
city: Memphis
country: United States
facility: Clinical Neuroscience Solutions, Inc.
state: Tennessee
city: Austin
country: United States
facility: FutureSearch Clinical Trials, LP
state: Texas
city: Houston
country: United States
facility: Claghorn-Lessem Research Clinic
state: Texas
city: Burlington
country: United States
facility: Fletch Allen Health Care, Dept. of Psychiatry, Univ. of Vermont
state: Vermont
Study officials:
affiliation: Fletcher Allen Health Care, Dept. of Psychiatry
name: Paul Newhouse, MD
role: PRINCIPAL_INVESTIGATOR
References: